Korro Bio, Inc. (KRRO)

Market Cap	410.05M
Revenue (ttm)	n/a
Net Income (ttm)	-87.81M
Shares Out	9.37M
EPS (ttm)	-11.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,384
Open	42.86
Previous Close	43.12
Day's Range	42.86 - 44.09
52-Week Range	30.01 - 98.00
Beta	n/a
Analysts	Strong Buy
Price Target	133.83 (+205.76%)
Earnings Date	Nov 12, 2024

About KRRO

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 3, 2019
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: KRRO
• Website: https://www.korrobio.com

Analyst Forecast

According to 7 analysts, the average rating for KRRO stock is "Strong Buy." The 12-month stock price forecast is $133.83, which is an increase of 205.76% from the latest price.

Price Target

$133.83

(205.76% upside)

Analyst Consensus: Strong Buy